The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population.
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
In 2022, the first and second most reported zoonoses in humans were campylobacteriosis and salmonellosis, respectively. The number of cases of campylobacteriosis and salmonellosis remained stable in comparison with 2021.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12 - 18 November 2023 and includes updates on SARS-CoV-2 variant classification, West Nile virus, multistate outbreak of salmonella, and an overview of respiratory virus epidemiology in the EU/EEA.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).